• Ticker

    Advertisement Find a Broker - Visit the DailyFinance Broker Center
DJIA 12,454.83 -74.92 -0.60%
NASDAQ 2,837.53 -1.85 -0.07%
S&P 500 1,317.82 -2.86 -0.22%

$6.28 $0.20 (3.29%)

REAL-TIME: Last trade at

Protalix BioTherapeutics, Inc.

AMEX:PLX

Jump to this page for:

Related Resources

Tel Aviv Stock Exchange and Nasdaq co-host a conference

5/17/2012 by Theflyonthewall.com

Auriga Reiterates a 'Buy' on Protalix BioTherapeutics (PLX); Eyes on Elelyso launch in U.S.

5/10/2012 by StreetInsider.com

Protalix BioTherapeutics to Present at Three Upcoming Healthcare Conferences

5/10/2012 by StockHouse

Protalix BioTherapeutics to Present at Three Upcoming Healthcare Conferences

5/10/2012 by StockWatch

Protalix BioTherapeutics to Present at Three Upcoming Healthcare Conferences

5/10/2012 by GlobeNewswire

This Biopharmaceutical Could Be Something Special

5/8/2012 by Seeking Alpha

Pfizer Should Rise On New Gaucher Drug, Due Out In 2013

5/7/2012 by Seeking Alpha

Protalix execs sell shares

5/6/2012 by Globes - Israel

Protalix upgraded to Buy from Hold at Auriga

5/4/2012 by Theflyonthewall.com

Auriga Upgrades Protalix BioTherapeutics (PLX) to Buy

5/4/2012 by StreetInsider.com

Biotech Stock Mailbag: Exelixis, Protalix, Arena

5/4/2012 by TheStreet.com

Apple, Intel, Protalix: Learning Lessons With Options

5/2/2012 by Seeking Alpha

Protalix's FDA Approval And 1-Year Price Target

5/2/2012 by Seeking Alpha

FDA approves Pfizer, Protalix drug for Gaucher disease

5/2/2012 by Drug Store News

Protalix Soars Most on Record on FDA Approval: Tel Aviv Mover

5/2/2012 by Bloomberg.com

Protalix target raised to $11 from $9 at Oppenheimer

5/2/2012 by Theflyonthewall.com

Protalix downgraded to Hold from Buy at Canaccord

5/2/2012 by Theflyonthewall.com

Protalix to host conference call

5/2/2012 by Theflyonthewall.com

Protalix BioTherapeutics to Review FDA Approval of ELELYSO(TM)

5/1/2012 by GlobeNewswire

Pfizer And Protalix BioTherapeutics Announce FDA Approval Of ELELYSO™ (taliglucerase alfa) For The Treatment Of Gaucher Disease

5/1/2012 by Business Wire

CBS Earnings Beat & Media Stocks

5/1/2012 by CNBC Video

Protalix, Pfizer Gaucher treatment approved by FDA

5/1/2012 by Theflyonthewall.com

Traders Eye Protalix BioTherapeutics (PLX) Ahead of FDA PDUFA Date

5/1/2012 by StreetInsider.com

US broker cuts Protalix on eve of FDA announcement

5/1/2012 by Globes - Israel

Shire's stumble could help Protalix on Gaucher's treatment

4/29/2012 by Globes - Israel

Protalix With Higher Chances To Get Approved After Shire's News

4/26/2012 by Seeking Alpha

Biotechs On The Move For Today

4/25/2012 by Seeking Alpha

Canaccord Genuity Reiterates a 'Buy' on Protalix BioTherapeutics (PLX); U.S. Tali Approval May Unlock Potential

4/19/2012 by StreetInsider.com

MAP Pharmaceutical: Timeline Of The NDA Resubmission

4/18/2012 by Seeking Alpha

Wednesday, April 18th Bio-Pharma Mover Watch List

4/18/2012 by Seeking Alpha

6 Biotech Stocks With Huge Potential In May

4/11/2012 by Seeking Alpha

Bio-Pharma Catalyst Trades That Offer Decent Short-Term Gains

4/9/2012 by Seeking Alpha

Focus On Upcoming FDA Drug Approval And Advisory Dates

4/4/2012 by Seeking Alpha

Protalix: What You Need To Know Ahead Of The May 1 PDUFA Date

3/20/2012 by Seeking Alpha

Protalix BioTherapeutics Sets Record Date for Annual Meeting of Shareholders

3/16/2012 by StockWatch

Protalix BioTherapeutics Sets Record Date for Annual Meeting of Shareholders

3/16/2012 by GlobeNewswire

"Protalix has 70% chance of obtaining FDA approval"

3/5/2012 by Globes - Israel

Auriga Reiterate a 'Buy' on Protalix BioTherapeutics (PLX); No Material Changes in 10-K

3/1/2012 by StreetInsider.com

Protalix BioTherapeutics to Participate at Two Upcoming Global Healthcare Conferences

2/23/2012 by GlobeNewswire

Potentialy Good Entry Point For Protalix Bio Therapeutics

2/22/2012 by Seeking Alpha
See More Articles...